BioNTech SE (22UA) — Capital Reinvestment Ratio
BioNTech SE (22UA) has a Capital Reinvestment Ratio of 0.20x as of December 2025, meaning it reinvests 0% of its operating cash flow (€309.50 Million) in capital expenditures (€62.10 Million). Check tangible net worth ratio of BioNTech SE to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
BioNTech SE Capital Reinvestment Ratio (2021–2025)
This chart tracks BioNTech SE's Capital Reinvestment Ratio across 5 annual periods. For the full cash flow conversion analysis, see 22UA cash flow conversion.
Annual Capital Reinvestment Ratio for BioNTech SE (2021–2025)
Year-by-year Capital Reinvestment Ratio for BioNTech SE from 2021 to 2025. See BioNTech SE (22UA) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 1.64x | €456.00 Million | €749.00 Million | ▼ -24.6% |
| 2024 | 2.18x | €207.70 Million | €452.30 Million | ▲ +1558.0% |
| 2023 | 0.13x | €5.37 Billion | €705.50 Million | ▲ +390.9% |
| 2022 | 0.03x | €13.58 Billion | €363.30 Million | ▼ -81.3% |
| 2021 | 0.14x | €889.70 Million | €127.50 Million | — |